

Supplemental Table 1: HCV drugs included in the algorithm
Daclatasvir (Daklinza)
Elbasvir-Grazoprevir (Zepatier)
Ombitasvir-Paritaprevir-Ritonavir (Technivie)
Ribavirin (Copegus, Rebetol, Ribasphere, Ribapak)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir (Viekira Pak)
Sofosbuvir-Velpatasvir-Voxilaprevir (Vosevi)
Simeprevir (Olysio)
Glecaprevir-Pibrentasvir (Mavyret)
Ledipasvir-Sofosbuvir (Harvoni)
Sofosbuvir (Sovaldi)
Sofosbuvir-Velpatasvir (Epclusa)
Interferon alpha-2b
Interferon alphacon-1 (Infergen)
Pegylated Interferon alpha-2a
Pegylated Interferon alpa-2b

Supplemental Table 2: Barriers to starting treatment at Mount Sinai among 149 candidates who did not start treatment during the follow-up period			
	Enrolled in our care coordination program (n=42)	Not enrolled in our care coordination program (n=107)	Total (n=149)

Competing medical priorities	7	49	56
Cleared HCV spontaneously	1	2	3
Died	6	11	17
Declined treatment or were lost to follow up	15	26	41
Transferred to care elsewhere	3	12	15
Delays due to missed appointments, comorbidities, or COVID-19	10	7	17

Supplemental Table 3: Barriers to completing treatment at Mount Sinai among 32 patients who started but did not complete treatment			
	Enrolled in our care coordination program (n=20)	Not enrolled in our care coordination program (n=12)	Total (n=32)
Competing medical priorities	0	2	2
Died	2	1	3
Became incarcerated	1	0	1
Lost to follow up	11	6	17
Transferred to care elsewhere	0	1	1
Stopped treatment, but achieved an SVR	6	2	8